A Prospective Multicenter Single-Arm Observational Registry Study Assessing the Safety and Efficacy of FIREHAWK Biodegradable Polymer Target-release Rapamycin-eluting Stent for the Treatment of Coronary Artery Disease: TARGET II

Trial Profile

A Prospective Multicenter Single-Arm Observational Registry Study Assessing the Safety and Efficacy of FIREHAWK Biodegradable Polymer Target-release Rapamycin-eluting Stent for the Treatment of Coronary Artery Disease: TARGET II

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 02 Nov 2017

At a glance

  • Drugs Sirolimus (Primary)
  • Indications Angina pectoris; Coronary artery disease; Coronary artery restenosis; Ischaemia; Myocardial infarction; Unstable angina pectoris
  • Focus Therapeutic Use
  • Acronyms TARGET-II
  • Sponsors MicroPort Medical
  • Most Recent Events

    • 02 Nov 2017 Results of a pooled analysis assessing 5-year outcomes in large cohort of patients from TARGET I and TARGET II (n=947) presented at the 29th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics
    • 10 Apr 2012 Planned number of patients changed from 1100 to 995 as reported by ClinicalTrials.gov.
    • 10 Apr 2012 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top